Jérôme Castandet

Jérôme Castandet

Auto-generated profile, based on publicly available information

Jérôme Castandet

Antabio SAS, 436 rue Pierre et Marie Curie, 31670 Labège, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2018 in ACS Infectious Diseases
Verified
Journal Article
Open access
SLSimon Leiris
Simon Leiris
ACAlicia Coelho
Alicia Coelho
JCJérôme Castandet
Jérôme Castandet
MBMaëlle Bayet
Maëlle Bayet
CLClarisse Lozano
Clarisse Lozano
DDDavid T. Davies
David T. Davies
The clinical effectiveness of carbapenem antibiotics such as meropenem is becoming increasingly compromised by the spread of both metallo β-lactamase (MBL) and serine β-lactamase (SBL) enzymes on mobile genetic elements, stimulating research to find new β-lactamase inhibitors to be used in conjunction with carbapenems and other β-lactam antibiotics. Herein we describe our initial exploration of a novel chemical series of metallo β-lactamase inhibitors, from concept through to efficacy in a survival model using an advanced tool compound (ANT431) in conjunction with meropenem.



20 January 2023 in ACS Infectious Diseases
Verified
Journal Article
Open access
MEMartin J. Everett
Martin J. Everett
DDDavid T. Davies
David T. Davies
SLSimon Leiris
Simon Leiris
NSNicolas Sprynski
Nicolas Sprynski
ALAgustina Llanos
Agustina Llanos
MLMarc Lemonnier
Marc Lemonnier
LasB elastase is a broad-spectrum exoprotease and a key virulence factor of Pseudomonas aeruginosa, a major pathogen causing lung damage and inflammation in acute and chronic respiratory infections. Here, we describe the chemical optimization of specific LasB inhibitors with druglike properties and investigate their impact in cellular and animal models of P. aeruginosa infection. Competitive inhibition of LasB was demonstrated through structural and kinetic studies. In vitro LasB inhibition was confirmed with respect to several host target proteins, namely, elastin, IgG, and pro-IL-1β. Furthermore, inhibition of LasB-mediated IL-1β activation was demonstrated in macrophage and mouse lung infection models. In mice, intravenous administration of inhibitors also resulted in reduced bacterial numbers at 24 h. These highly potent, selective, and soluble LasB inhibitors constitute valuable tools to study the proinflammatory impact of LasB in P. aeruginosa infections and, most importantly, show clear potential for the clinical development of a novel therapy for life-threatening respiratory infections caused by this opportunistic pathogen.

15 January 2021 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SLSimon Leiris
Simon Leiris
DDDavid T. Davies
David T. Davies
NSNicolas Sprynski
Nicolas Sprynski
JCJérôme Castandet
Jérôme Castandet
LBLilha Beyria
Lilha Beyria
MEMartin Everett
Martin Everett